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Abstract
Aims/hypothesis Reversion from prediabetes to normoglycaemia is accompanied by an improvement in cardiovascular risk
factors, but it is unclear whether this translates into a reduction in risk of cardiovascular disease (CVD) events or death.
Hence, we studied the probability of reversion from prediabetes to normoglycaemia and the associated risk of future CVD and
death using data from the Whitehall II observational cohort study.
Methods Three glycaemic criteria for prediabetes (fasting plasma glucose [FPG] 5.6–6.9 mmol/l, 2 h plasma glucose [2hPG]
7.8–11.0 mmol/l, and HbA1c 39–47 mmol/mol [5.7–6.4%]) were assessed in 2002–2004 and 2007–2009 for 5193 participants
free of known diabetes at enrolment. Among participants with prediabetes in the first examination, we calculated the probability
of reversion to normoglycaemia by re-examination according to each glycaemic criterion. Poisson regression analysis was used
to estimate and compare incidence rates of a composite endpoint of a CVD event or death in participants with prediabetes who did
vs did not revert to normoglycaemia. Analyses were adjusted for age, sex, ethnicity and previous CVD.
Results Based on the FPG criterion, 820 participants had prediabetes and 365 (45%) of them had reverted to normoglycaemia in
5 years. The corresponding numbers were 324 and 120 (37%) for the 2hPG criterion and 1709 and 297 (17%) for the HbA1c
criterion. During a median follow-up of 6.7 (interquartile range 6.3–7.2) years, 668 events of non-fatal CVD or death occurred
among the 5193 participants. Reverting from 2hPG-defined prediabetes to normoglycaemia vs remaining prediabetic or
progressing to diabetes was associated with a halving in event rate (12.7 vs 29.1 per 1000 person-years, p = 0.020). No associ-
ation with event rate was observed for reverting from FPG-defined (18.6 vs 18.2 per 1000 person-years, p = 0.910) or HbA1c-
defined prediabetes to normoglycaemia (24.5 vs 22.9 per 1000 person-years, p = 0.962).
Conclusions/interpretation Most people with HbA1c-defined prediabetes remained prediabetic or progressed to diabetes during
5 years of follow-up. In contrast, reversion to normoglycaemia was frequent among people with FPG- or 2hPG-defined predi-
abetes. Only reversion from 2hPG-defined prediabetes to normoglycaemia was associated with a reduction in future risk of CVD
and death.
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Introduction
Prediabetes increases the risk of cardiovascular disease (CVD)
and mortality [1, 2], and reversion from prediabetes to
normoglycaemia is related to an improvement in a range of
cardiovascular risk factors [3]. However, whether reversion
translates into a reduction in risk of CVD or death has yet to
be determined. To fill this knowledge gap, the current analysis
explored the probability of reversion from prediabetes to
normoglycaemia from different definitions of prediabetes
and the associated risk of future CVD and death in a longitu-
dinal follow-up of the well-described Whitehall II observa-
tional cohort study.
Methods
Study population The Whitehall II study is an occupational
cohort of 10,308 British civil servants who have been followed
up with clinical examinations every 5 years since 1985 [4]. The
current analysis utilised data from phase 7 (2002–2004) and
phase 9 (2007–2009), when fasting plasma glucose (FPG),
2 h plasma glucose (2hPG) and HbA1c were measured. From
the 6967 participants at phase 7, we excluded 671 (9.6%) who
did not participate at phase 9, 392 (5.6%) with known diabetes
at phase 7, 684 (9.8%) who could not be classified with
normoglycaemia, prediabetes or diabetes at both phases on at
least one criterion, and 27 (0.4%) with screen-detected diabetes
according to all the three criteria at phase 7, leaving 5193
(74.5%) of the phase 7 participants for analysis (ESM Fig. 1).
For the analyses of FPG and 2hPG, participants had to have
fasted for ≥8 h before the clinical examinations. The University
College London Ethics Committee reviewed and approved the
study. Written informed consent was obtained from all partici-
pants at each study phase.
Measurements and definitions Participants underwent a stan-
dard 75 g OGTT with measurement of FPG and 2hPG using
the glucose oxidase method [4]. HbA1c was measured in
whole blood, drawn into BD Vacutainers (Becton Dickinson,
Winnersh, UK), using the validated Tosoh G8 high-
performance ion-exchange liquid chromatography platform
(Tosoh Bioscience, Tessenderlo, Belgium).
Prediabetes was defined as FPG 5.6–6.9 mmol/l, 2hPG 7.8–
11.0 mmol/l and/or HbA1c 39–47 mmol/mol (5.7–6.4%) ac-
cording to criteria from the ADA [5]. For each of the three
criteria, normoglycaemia and diabetes were defined as values
below and above the cut-off points for prediabetes, respectively.
Diabetes could also be diagnosed by a doctor outside the study.
The primary outcome was a composite endpoint of a CVD
event or death between 2007–2009 (phase 9) and the end of
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follow-up (30 June 2015). Adjudicated CVD events included
fatal and non-fatal myocardial infarction and stroke [2]. All-
cause mortality was obtained from the NHS Central Registry,
which provided information on the cause and date of death.
Statistical analysis All analyses were conducted separately for
the three glycaemic criteria, in accordance with the guidelines
from ADA [5] and the International Expert Committee (IEC)
[6], which suggest that the different criteria to define predia-
betes and diabetes should not be combined. For each criterion,
participants with screen-detected diabetes at baseline by the
given glycaemic criterion were excluded.
Among individuals with prediabetes at phase 7, we calcu-
lated the probability of reversion to normoglycaemia at the
phase 9 re-examination approximately 5 years later. Poisson
regression analysis with log(person time) as offset was used to
estimate and compare incidence rates of future CVD or death
in individuals with prediabetes who did or did not revert to
normoglycaemia. The follow-up period of each participant
was split into 1 year age bands to account for the non-
constant effect of age over time on CVD risk and mortality.
Analyses were adjusted for age, sex, ethnicity and previous
CVD. A complete case approach was used.
All participants with 2hPG available also had measure-
ments of FPG and HbA1c (but not vice versa). Among partic-
ipants with 2hPG-defined prediabetes and elevated FPG and/
or HbA1c, we compared event rates between participants who
did or did not revert to normoglycaemia on FPG and/or
HbA1c, without normalising 2hPG (ESM Fig.1).
We further estimated the associations of changes in FPG,
2hPG or HbA1c from phase 7 to phase 9 with risk of future
CVD or death, excluding participants with known diabetes at
phase 9 because they were likely to be receiving treatment.
Statistical analyses were performed in R, version 3.4.1 (R
Foundation for Statistical Computing, Vienna, Austria).
Results
The study population was predominantly men (73%) and of
white ethnicity (93%), 769 (15%) had pre-existing CVD, and
the average age was 60 years (range 50–73 years) at the first
clinical examination (phase 7). During a median follow-up of
6.7 (interquartile range 6.3–7.2) years, 668 events of non-fatal
CVD or death occurred among the 5193 participants.
Comparing normoglycaemia vs prediabetes by each
glycaemic criterion (Table 1), more men than women had
prediabetes defined by FPG whereas no sex difference was
observed for prediabetes defined by 2hPG or HbA1c.
Participants with 2hPG- or HbA1c-, but not FPG-defined pre-
diabetes were older (p < 0.001) and more likely to be of non-
white e thnic i ty (p ≤ 0.044) compared with thei r
normoglycaemic counterparts.
FPG criterion Among 820 participants with FPG-defined pre-
diabetes at baseline, 365 (45%) reverted to normoglycaemia
and 111 (14%) progressed to diabetes at the 5 year re-exami-
nation. From the 5 year re-examination, median (interquartile
range) follow-up time was 6.7 (6.3–7.2) years, during which
96 (12%) developed CVD or died. Reverting from prediabetes
to normoglycaemia was not associated with a difference in
rate of developing CVD or dying vs remaining prediabetic
or progressing to diabetes (18.6 vs 18.2 per 1000 person-
years, p = 0.962) (Fig. 1a, ESM Table 1).
2hPG criterion Among 324 participants with 2hPG-defined
prediabetes at baseline, 120 (37%) reverted to normoglycaemia
and 73 (23%) progressed to diabetes after 5 years. Follow-up
time for CVD and death was 6.7 (6.4–7.2) years, during which
47 (15%) developed CVD or died. Reverting from prediabetes
to normoglycaemia was associated with a halving of the event
rate vs remaining prediabetic/progressing to diabetes (12.7 vs
29.1 per 1000 person-years, p = 0.020), and was largely un-
changed after adjustment for age, sex, ethnicity and previous
CVD (Fig. 1a, ESM Table 1).
Among the 324 participants with prediabetes at baseline,
220 also had prediabetes according to the FPG and/or HbA1c
criteria. At the 5 year re-examination, 21 (10%) of these had
reverted to normoglycaemia according to the FPG and/or
HbA1c criteria but not according to the 2hPG criterion.
However, improvement in FPG or HbA1c without improve-
ment in 2hPGwas not associated with a lower event rate (32.1
vs 28.8 per 1000 person-years, respectively, p = 0.835).
HbA1c criterion Among 1709 participants with HbA1c-defined
prediabetes at baseline, 297 (17%) reverted to normoglycaemia
and 233 (14%) progressed to diabetes after 5 years. Follow-up
time for an event was 6.7 (6.3–7.2) years, during which 258
(15%) developed CVD or died. Reverting from prediabetes to
normoglycaemia was not associated with a difference in rate of
developingCVDor dying vs remaining prediabetic/progressing
to diabetes (24.5 vs 22.9 per 1000 person-years, p = 0.962)
(Fig. 1a, ESM Table 1).
The analysis of absolute changes in FPG, 2hPG or HbA1c
from phase 7 to phase 9 confirmed the results (Fig. 1b, ESM
Table 2).
Discussion
In this cohort study, reversion from 2hPG-defined prediabetes
to normoglycaemia was associated with an approximately
50% lower risk of a CVD event or death compared with re-
maining with prediabetes or progressing to diabetes. Despite
prediabetes being a known risk factor for CVD, we found that
reversion from FPG- or HbA1c-defined prediabetes to
normoglycaemia was not associated with a lower risk of
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CVD or death. Outside pregnancy, the OGTT has largely been
eliminated for diagnosing diabetes, particularly with the recent
widespread standardisation of the HbA1c assay. However, our
findings suggest that identification of people with elevated
2hPG should be considered for CVD risk stratification either
by re-introducing the OGTT for diagnosing prediabetes and
diabetes or by other methods [7, 8].
Our results support previous findings from the Diabetes
Prevention Program (DPP), where individuals with 2hPG-
defined prediabetes who reverted to normoglycaemia experi-
enced a concomitant reduction in their cardiovascular risk
profile [9]. Previous observations from a general Dutch pop-
ulation also suggested that 2hPG levels are more strongly
associated with all-cause and cardiovascular mortality than
Fig. 1 Rate ratios (RRs) of an
event (CVD or death) for
reverting from prediabetes to
normoglycaemia vs not reverting
(a) or for decreasing 1 SD in
glycaemic measure over 5 years
from phase 7 to phase 9 (b). Grey:
unadjusted RR; light blue:
adjusting for age and sex; dark
blue: further adjusting for
previous CVD. The RR for 1 SD
decrease (b) is further adjusted for
baseline glycaemia in all the
analyses. The x-axis is on a
natural logarithmic scale
Table 1 Characteristics of study participants at the first clinical examination (phase 7) by glycaemic criterion
Characteristic FPG criterion 2hPG criterion HbA1c criterion
Normoglycaemia Prediabetes Normoglycaemia Prediabetes Normoglycaemia Prediabetes
n 2130 820 2154 324 3337 1709
Men (%) 70.0 (68.1, 72.0) 83.9 (81.2, 86.4) 75.7 (73.8, 77.5) 76.2 (71.2, 80.8) 72.6 (71.0, 74.1) 73.6 (71.5, 75.7)
White ethnicity (%) 92.5 (91.3, 93.6) 93.2 (91.2, 94.8) 93.1 (91.9, 94.1) 89.8 (86.0, 92.9) 96.3 (95.6, 96.9) 89.4 (87.9, 90.8)
Age (years) 60.2 ± 5.8 60.6 ± 5.8 59.6 ± 5.6 62.0 ± 6.1 60.2 ± 5.7 61.6 ± 5.9
BMI (kg/m2) 24.0 ± 3.1 24.9 ± 3.2 24.0 ± 3.1 24.9 ± 3.1 23.9 ± 3.0 24.6 ± 3.3
Total cholesterol (mmol/l) 5.7 ± 1.0 5.8 ± 1.0 5.7 ± 1.0 5.7 ± 1.0 5.7 ± 1.0 5.8 ± 1.0
HDL-cholesterol (mmol/l) 1.6 ± 0.5 1.5 ± 0.4 1.6 ± 0.4 1.5 ± 0.4 1.6 ± 0.5 1.5 ± 0.4
LDL-cholesterol (mmol/l) 3.5 ± 0.9 3.6 ± 0.9 3.6 ± 0.9 3.6 ± 0.9 3.5 ± 0.9 3.6 ± 0.9
Triacylglycerols (mmol/l) 1.1 (0.8–1.5) 1.2 (0.9–1.7) 1.1 (0.8–1.5) 1.3 (0.9–1.85) 1.1 (0.8–1.5) 1.2 (0.9–1.8)
Systolic BP (mmHg) 126.0 ± 16.3 131.2 ± 16.4 125.6 ± 15.7 130.6 ± 16.7 126.3 ± 16.1 129.0 ± 16.3
Diastolic BP (mmHg) 73.6 ± 10.3 76.5 ± 10.1 73.7 ± 10.3 75.0 ± 10.2 73.8 ± 10.4 74.9 ± 10.2
FPG (mmol/l) 5.0 ± 0.3 5.9 ± 0.3 5.3 ± 0.5 5.6 ± 0.7 5.2 ± 0.5 5.5 ± 0.6
2hPG (mmol/l) 5.9 ± 1.5 6.9 ± 2.0 5.7 ± 1.1 8.9 ± 0.9 5.9 ± 1.5 6.6 ± 1.9
HbA1c (mmol/mol) 33.0 ± 4.0 35.0 ± 5 33.0 ± 4 36.0 ± 5 35.0 ± 3.0 42.0 ± 2.0
HbA1c (%) 5.2 ± 0.4 5.4 ± 0.4 5.2 ± 0.4 5.4 ± 0.4 5.4 ± 0.3 6.0 ± 0.2
Previous CVD (%) 12.4 (11.1, 13.9) 17.1 (14.6, 19.8) 12.5 (11.2, 14) 18.5 (14.4, 23.2) 11.4 (10.4, 12.6) 18.0 (16.2, 19.9)
Family history of DM (%) 9.3 (8.1, 10.6) 12.3 (10.1, 14.8) 9.1 (7.9, 10.4) 10.0 (6.9, 13.8) 8.4 (7.4, 9.4) 12.2 (10.7, 13.9)
Current smoker (%) 8.0 (6.9, 9.2) 7.9 (6.2, 10.0) 7.7 (6.6, 8.9) 4.6 (2.6, 7.5) 6.0 (5.2, 6.9) 9.2 (7.9, 10.7)
Alcohol intake (units/week) 8.0 (2.0–16.0) 12.0 (5.0–21.0) 10.0 (4.0–18.0) 9.0 (3.0–17.0) 10.0 (4.0–18.0) 8.0 (2.0–16.0)
Antihypertensive treatment (%) 19.5 (17.9, 21.3) 28.2 (25.1, 31.4) 18.4 (16.8, 20.1) 33.3 (28.2, 38.8) 17.9 (16.6, 19.3) 26.6 (24.5, 28.8)
Lipid-lowering treatment (%) 7.8 (6.7, 9.0) 13.4 (11.2, 15.9) 7.5 (6.4, 8.7) 15.4 (11.7, 19.8) 6.9 (6.0, 7.8) 13.4 (11.8, 15.1)
Data are means±SD, medians (25–75% percentiles; IQR) or proportions (95% CI)
HbA1c: normoglycaemia: <39 mmol/mol (5.7%), prediabetes 39–47 mmol/mol (5.7–6.4%), Fasting plasma glucose: normoglycaemia: <5.6 mmol/l,
prediabetes 5.6–6.9 mmol/l, 2hPG: normoglycaemia: <7.8 mmol/l, prediabetes 7.8–11.0 mmol/l
DM, diabetes mellitus
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FPG or HbA1c levels in the non-diabetic range [10]. These
results may reflect underlying pathophysiological differences
in, for example, insulin resistance, which is more pronounced
in elevated 2hPG than in elevated FPG and HbA1c [11].
We found reversion to normoglycaemia from HbA1c-
defined prediabetes to be less likely than from FPG-
or 2hPG-defined prediabetes. While our results on
reversion rates for FPG- and 2hPG-defined prediabetes
are consistent with previous findings [12], evidence on
the ability to revert from HbA1c-defined prediabetes to
normoglycaemia is scarce [12]. A Japanese study
reported a reversion rate of 32% in a study population
that was, on average, 10 years younger than the partici-
pants of the Whitehall II study [12]. There is less day-to-
day variation in HbA1c, and levels in the non-diabetic
range may largely be explained by non-glycaemic
factors, such as age and ethnicity [13], and may therefore
not be modifiable to the same degree as FPG and 2hPG
levels.
We have chosen not to combine different definitions
of prediabetes and assess the impact of overall reverting
to normoglycaemia. Combining definitions is not in
accordance with ADA and IEC and will greatly inflate
the prevalence of prediabetes [14]. Furthermore, the
corresponding state of normoglycaemia needs to be
defined as normal values on all three criteria, which
may not be relevant in clinical practice. Alternatively,
specific states of prediabetes and normoglycaemia will
have to be applied, resulting in numerous transition
possibilities for which this study is not powered to
examine (ESM Fig. 2 and 3).
Results from the current analysis are strengthened by
the longitudinal, well-described, large population size
and the validated ascertainment of CVD events.
Nevertheless, reversion cannot be ascribed to interven-
tion effects, since the cohort is strictly observational, and
all conclusions remain associative and not necessarily
causative. There is still controversy between different
diabetes organisations with respect to whether HbA1c
or FPG should be used to define prediabetes. Our results
did not show a reduced risk of CVD or death when
people with either HbA1c- or FPG-defined prediabetes
were able to revert to normoglycemia, based on the
respective criterion. On the other hand, we found reversion
from 2hPG-defined prediabetes to be associated with a
halving of the risk of CVD and death. Although the different
diagnostic criteria for prediabetes are likely to remain, the
current results would contend that only reversion from
2hPG-defined prediabetes to normoglycaemia is sensitive
enough to detect cardiovascular benefit.
Guidelines for people with diabetes are increasingly
comprehensive [5], and accordingly, the incidence of
complications has dramatically decreased over the past
20 years [15]. In contrast, the lack of accepted guidelines
for people with prediabetes has made the prevalence of
diabetes-related complications now virtually identical for
people with prediabetes vs those with diabetes [16]. The
current findings highlight the reduced risk for CVD and
death associated with reversion from 2hPG-defined
prediabetes, specifically, to normoglycaemia. These find-
ings have important implications for additional cardio-
vascular risk stratification and intervention in a land-
scape that has become increasingly controversial [17].
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